US · guidance

CMS Pub. 100-04, ch. 32, § 300

Billing Requirements for Ocular Photodynamic Therapy (OPT) with

activein force · 2026-08-25 – presentas-observed

Verteporfin

(Rev. 2728, Issued: 06-14-13-Effective: 04-03-13, Implementation: 07-16-13)

Ocular Photodynamic Therapy (OPT) is used in the treatment of ophthalmologic diseases;

specifically, for age-related macular degeneration (AMD), a common eye disease among the

elderly. OPT involves the infusion of an intravenous photosensitizing drug called Verteporfin,

followed by exposure to a laser. For complete Medical coverage guidelines, see National

Coverage Determinations (NCD) Manual (Pub 100-03) § 80.2 through 80.3.1.

History

(Rev. 2728, Issued: 06-14-13-Effective: 04-03-13, Implementation: 07-16-13)

Provenance

Source: cms.gov
Retrieved: 2026-08-25
Edition: iom-2026-08-25
Content hash: a98a14a508a36e7f5415e656d66a6345aa89c63b60c1186b1b544e2b0db361f3

View the official source →

The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.

Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.

Coverage · API docs